Journal
ONCOTARGET
Volume 7, Issue 11, Pages 13060-13068Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.7421
Keywords
CTLA-4; CD28; nasopharyngeal carcinoma; immunohistochemistry; prognostic factor
Categories
Funding
- National Natural Science Foundation of China [81425018, 81072226]
- 863 Project [2012AA02A501, 2012AA02A206]
- National Key Basic Research Program of China [2013CB910304, 81201629]
- Sci-Tech Project Foundation of Guangdong Province [2014A020212103, 2011B031800161]
- Special Support Plan of Guangdong Province [2014TX01R145]
- Sci-Tech Project Foundation of Guangzhou City [2011J4300100]
- Fundamental Research Funds for the Central Universities, Sun Yat-Sen University Clinical Research 5010 Program [201315, 2015010]
- Fundamental Research Funds for the Central Universities [15ykpy36]
- Clinical Research of Special Funds of Wu Jieping Medical Foundation [320.6750.14270]
- CSCO-Merck Serono Oncology Research Fund [Y-MT2015-023]
- China Scholarship Council [201506385044]
Ask authors/readers for more resources
The expression levels of CTLA-4 and CD28 were analyzed in 191 nasopharyngeal carcinoma (NPC) patients diagnosed and treated at our hospital between January 2010 and November 2011. The 3-year overall survival (OS) rate (91.4% vs. 81.2%, p = 0.043), failure-free survival (FFS) rate (82.8% vs. 68.0%, p = 0.009) and distant failure-free survival (D-FFS) rate (85.8% vs. 72.3%, p = 0.006) in the low tumor CTLA-4 expression group was higher than in the high tumor CTLA-4 group. There were no differences between the locoregional failure-free survival (LR-FFS) rates in the high and low tumor CTLA-4 expression groups. Moreover, no differences in the OS, FFS, D-FFS, or LR-FFS were observed between the groups with high and low lymphocyte CTLA-4 levels, high and low tumor CD28 levels, or high and low lymphocyte CD28 levels. Cox regression analysis confirmed the prognostic value of tumor CTLA-4 expression, particularly for D-FFS, in NPC patients (p = 0.044). NPC patients with high tumor CTLA-4 expression had a poorer prognosis than those with low expression.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available